Skip to main content

Market Overview

BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate

BMO Bullish On 'Blockbuster Potential' Of Stealth BioTherapeutics' Lead Candidate

Stealth BioTherapeutics Corp (NASDAQ: MITO)'s lead drug elamipretide has “blockbuster potential” in primary mitochondrial dysfunction, or PMM, according to BMO Capital Markets.

The Analyst

BMO Capital Markets’ Matthew Luchini initiated coverage of Stealth BioTherapeutics with an Outperform rating and $29 price target. 

The Thesis

Mitochondria, which are present in almost every cell in the body, are responsible for 90 percent of the body’s energy needs. Stealth is focused on primary mitochondrial diseases, which can be present at birth or have a later onset, Luchini said in a Tuesday note. 

The company announced solid Phase 2 data in PMM and is scheduled to report Phase 3 data by the close of 2019, the analyst said.

The ongoing trial is “relatively de-risked,” and if the results are favorable, even a single Phase 3 study could support FDA approval, Luchini said. 

PMM represents a large market opportunity of about $1.2 billion in peak sales given that there are about 190,000 patients in the U.S. and EU with no approved treatment, the analyst said. 

Stealth is expected to commence a Phase 2 trial of elamipretide in geographic atrophy in the first quarter, with a data release possible by the end of 2020.  

Price Action

Stealth BioTherapeutics shares were down 4.79 percent at $14.30 at the time of publication Tuesday. 

Related Links:

Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate

The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Latest Ratings for MITO

May 2020H.C. WainwrightReiteratesBuy
Apr 2020NomuraMaintainsBuy
Apr 2020HC Wainwright & Co.UpgradesNeutralBuy

View More Analyst Ratings for MITO
View the Latest Analyst Ratings


Related Articles (MITO)

View Comments and Join the Discussion!

Posted-In: BMO Capital Markets Matthew LuchiniAnalyst Color Biotech Price Target Initiation Analyst Ratings General

Latest Ratings

CSTRPiper SandlerUpgrades24.0
NVAXHC Wainwright & Co.Maintains294.0
NLOKB of A SecuritiesUpgrades30.0
CCEPDeutsche BankUpgrades67.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at